Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

2(28.6%)

7Total

Phase 1(5)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00637247Phase 2Completed

A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer

Role: lead

NCT00327288Phase 1Completed

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

Role: lead

NCT00697060Phase 2Withdrawn

A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer

Role: lead

NCT00327600Phase 1Completed

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Role: lead

NCT00327327Phase 1Completed

Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

Role: lead

NCT00327249Phase 1Completed

Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

Role: lead

NCT00327223Phase 1Completed

Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy

Role: lead

All 7 trials loaded